Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis.
Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis.
复制标题
非小细胞肺癌铂类化疗反应的药物基因组学：基因分型研究和汇总分析
DOI：
10.18632/oncotarget.9688
复制
发表时间：
2016-08-23
期刊：
影响因子：
--
通讯作者：
Liu Z
中科院分区：
文献类型：
--
作者：
Chen J;Wang Z;Zou T;Cui J;Yin J;Zheng W;Jiang W;Zhou H;Liu Z
已发表的数据显示，关于广泛研究的多态性与铂类药物化疗反应的相关性，结果不一致。我们的研究旨在通过在更大的样本量中检测SNP的基因型并总结全面的汇总分析来提供这些关联的可靠结论。采用SequenomMassARRAY技术对1024例NSCLC患者8个基因的13个SNP进行基因分型。39篇已发表的研究和我们的研究被纳入荟萃分析。XRCC 1 G1196基因GA或GG型患者的疗效优于AA型患者（基因分型研究：OR = 0.72，95%CI：0.53-0.96，P = 0.028; Meta分析：OR = 0.74，95%CI：0.62-0.89，P = 0.001）。XRCC 1C 580 T基因CT或TT型患者对铂类化疗的敏感性高于CC型患者（OR = 0.54，95%CI：0.37-0.80，P = 0.002）。XRCC 3 C18067 T基因型携带者中，CC基因型对铂类化疗的耐药率高于CT或TT基因型（OR = 0.69，95%CI：0.52-0.91，P = 0.009）。本研究提示，XRCC 1 G1196 A/C580 T和XRCC 3 C18067 T在NSCLC患者的铂类药物个体化化疗中应引起重视。
Published data showed inconsistent results about associations of extensively studied polymorphisms with platinum-based chemotherapy response. Our study aimed to provide reliable conclusions of these associations by detecting genotypes of the SNPs in a larger sample size and summarizing a comprehensive pooled analysis. 13 SNPs in 8 genes were genotyped in 1024 NSCLC patients by SequenomMassARRAY. 39 published studies and our study were included in meta-analysis. Patients with GA or GG genotypes of XRCC1 G1196 had better response than AA genotype carriers (Genotyping study: OR = 0.72, 95%CI: 0.53-0.96, P = 0.028; Meta-analysis: OR = 0.74, 95%CI: 0.62-0.89, P = 0.001). Patients carrying CT or TT genotypes of XRCC1 C580T could be more sensitive to platinum-based chemotherapy compared to patients with CC genotype (OR = 0.54, 95%CI: 0.37-0.80, P = 0.002). CC genotype of XRCC3 C18067T carriers showed more resistance to platinum-based chemotherapy when compared to those with CT or TT genotypes (OR = 0.69, 95%CI: 0.52-0.91, P = 0.009). Our study indicated that XRCC1 G1196A/C580T and XRCC3 C18067T should be paid attention for personalized platinum-based chemotherapy in NSCLC patients.